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Breast cancers are routinely subcategorised on the basis of clinical stage, cellular morphology and immunohistochemical analysis of a
small number of markers. The recent development of gene expression microarray and related technologies provides an opportunity
to perform more detailed profiling of the disease. It is anticipated that the molecular classification arising from such studies will be
more powerful than its pathological predecessor at confining treatment to those patients who are most likely to benefit. It is likely that
this will result in a much less frequent use of adjuvant chemotherapy. Furthermore, of those who do receive it, a higher proportion
will benefit. If adopted, this will offer considerable patient benefits in terms of reducing unnecessary toxicity and have major health
economic implications.
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Most cancer types, and breast cancer is no exception, can be
subcategorised by clinical stage and pathological subtype. These
categories can be correlated with survival data, which allows the
prediction of disease natural history and, to a lesser extent,
treatment response and benefit for a given patient. This is
fundamental to therapeutic decision-making in oncology and
increasingly allows treatment to be tailored on an individual
patient basis.
However, the standard methods for subtyping breast cancers
remain relatively crude. Clinical staging and routine pathology are
the principle indices used to identify those individuals at risk of
developing metastases and who should therefore be considered for
adjuvant chemotherapy. These features have been incorporated
into various standardised scoring algorithms (Galea et al, 1992;
Goldhirsch et al, 1998; Eifel et al, 2001). Their application,
however, results in the ‘over-treatment’ of many patients in whom
cure would have been achieved without chemotherapy or possibly
even endocrine treatment. This is illustrated by the Oxford
Overviews of systemic treatments that demonstrate a significant
proportion of long-term survivors in the untreated arms (Early
Breast Cancer Trialists’ Collaborative group, 1998a).
Another group of patients who receive treatment from which
they will not benefit are those who will develop metastatic disease
despite adjuvant cytotoxic treatment. Although staining for the
oestrogen and HER-2 receptors are powerful individual predictors
of response (and benefit from) tamoxifen and herceptin,
respectively, clinicians lack a marker that predicts those who will
benefit from chemotherapy.
Unlike standard methodologies that rely on a few pathological
features and immunohistochemical markers, molecular profiling
allows tumours to be defined by the expression pattern or genomic
alteration of thousands of genes simultaneously. With these
techniques comes the prospect of defining individual genes or
combinations of genes whose expression level(s) can discriminate
efficiently between clinically significant subtypes of breast tumours
requiring different treatment strategies.
Gene expression microarrays have been used extensively to
study breast cancer. The technical aspects of these approaches
have been reviewed extensively in the scientific literature (Schulze
and Downward, 2001). Here, we will consider the role of
expression microarray profiling in the definition of existing and
novel categories of breast cancer. In particular, we will address
how it may reduce the large number of breast cancer patients who
receive inappropriate, yet toxic treatments.
GENE EXPRESSION MICROARRAY EXPRESSION
PROFILING TO DEFINE SUBCATEGORIES OF
BREAST CANCERS
Broadly speaking, subclassification of cancers by gene expression
microarray analysis can be performed in one of two ways.
Microarray data from a selection of clinical samples may be
interrogated for ‘clusters’ of samples that are statistically
significantly related in terms of their expression profiles. Samples
that share expression profile features might be expected to share
phenotypic features such as those that can be clearly defined
pathologically, for example oestrogen receptor (ER) status, or
those that are less obvious, for example chemosensitivity. This
approach is referred to as an unsupervised analysis (or clustering)
(Quackenbush, 2001). In contrast, a supervised analysis begins
with designation of the samples to ‘labelled’ phenotypic sub-
categories. A search is then made to define a list of genes that are
distinct in their expression between the two ‘labelled’ groups and
those that can be used to distinguish between them. The
discriminatory accuracy of the list of genes defined in this way
can then be tested for its ability to separate the samples into the
defined groups on an independent set of samples (a ‘validation
set’). For example, the expression profile of samples from
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compared. A list of genes that are differentially expressed between
the two groups is obtained and then assessed for its ability to
predict response in a separate group of samples (Quackenbush,
2001).
Initial studies set out to demonstrate that breast cancers with
distinct pathological features could be ‘separated’ by microarray.
Several groups demonstrated that supervised data analysis can be
used to derive a set of genes that can distinguish ER-positive
cancers from ER-negative tumours (Gruvberger et al, 2001; West
et al, 2001; van ‘t Veer et al, 2002). While these studies were
important in validating the technology and developing the
methodology for data analysis, extensive expression profiling of
this nature is unlikely to replace standard immunohistochemical
assessment of ER status; smaller customized arrays, however,
consisting of tens not thousands of genes, or customized real-time
quantitative PCR platforms (‘gene-cards’) represent a more
realistic prospect as a clinically useful assay. These studies also
demonstrated, perhaps initially somewhat surprisingly, just how
different ER-positive breast cancer is from ER-negative cancers.
The fact that ER-positive and ER-negative tumours are so different
at the level of gene expression, suggests that these molecular
subtypes are entirely different disease entities, which perhaps arise
from distinct precursor cell types. Furthermore, only a few of the
genes that discriminate between ER-positive and ER-negative
tumours appear to be part of the ER signaling pathway, adding
further weight to the concept of distinct lineages for ER-positive
and ER-negative tumours (Gruvberger et al, 2001).
Known pathological subtypes can also be identified by clustering
using a selected panel of genes. In a recent study (Sorlie et al,
2003), which is an extension of the earlier work (Perou et al, 2000;
Sorlie et al, 2001), 115 malignant breast tumours were analysed
by hierarchical clustering and were shown to subdivide into
five subgroups, some of which had been previously recognised
and some of which were new entities. The distinction was
greatest between tumours showing high expression of ‘luminal
epithelial specific genes’, including ER, and those not expressing
these genes.
MOLECULAR PROFILING TO PREDICT DISEASE
RELAPSE
The use of gene expression microarray analysis has an obvious
potential role as a means of predicting relapse. The molecularly
Figure 1 Model for the effect of molecular profiling on numbers of
premenopausal women with node negative breast cancer receiving
chemotherapy, and associated benefit at 5 years. (A) The Oxford
overview of polychemotherapy (Early Breast Cancer Trialists’ Collaborative
group, 1998b) indicated that for 100 node-negative, premenopausal
women receiving chemotherapy according to standard criteria, at 5 years
three are cured by chemotherapy, 83.5 would have been alive without
chemotherapy and 13.5 die despite chemotherapy. With application of
molecular profiling to predict the outcome, these figures (for the same 100
people) would become 3, 22.5 (false-positive rate of 27% from van ‘t Veer
et al, 2002) and 13.5, respectively. If response could be predicted, the third
column would be reduced further to the false-positive rate for the
predictive profile used (here we have assumed that this is approximately as
for outcome profiling, that is 27%). The second column may be reduced
but this is difficult to estimate. This illustrates that much less chemotherapy
would be given. (B) This shows the proportional benefit of women
receiving chemotherapy according to the same criteria. Considering the
same 100 women, if outcome prediction with molecular profiling of breast
cancer was employed, the number treated would be reduced to 39,
resulting in an increase in the proportion cured (from three out of 100 to
three out of 39 or 8%). If it were possible to predict chemoresponsiveness,
it is possible that the number receiving chemotherapy would reduce further
from 39 to 29.5 (allowing for a false-positive rate equivalent to that seen in
the van ‘t Veer study). A reduction in the second column would probably
occur but is not shown. In this scenario, the proportion cured by
chemotherapy would be three out of 29.5, approximately 10% (a three-
fold increase), and the number of women treated has been reduced by
70%. Note that in neither figure has consideration been given to the false-
negative rate inherent in molecular profiling. It has been assumed that all
deaths occurring were breast cancer related.
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2003) were associated with differences in clinical outcome. This
suggests that subtypes derived by an unsupervised analysis are
indeed of clinical significance. Nevertheless, a list of discrimina-
tory genes useful as a ‘test’ of prognosis, is best obtained by a
supervised analysis. In a landmark study, van ‘t Veer et al (2002)
performed gene expression microarray analysis on 78 sporadic
lymph-node-negative tumours arising in women under the age of
55 years. Approximately half of the tumours had given rise to
metastases at 5 years. The study was particularly informative as
very few of the patient groups had received systemic treatment,
which is likely to benefit a molecular subset of patients and thereby
modify the outcome. Microarray analysis of these primary
tumours identified a list of 70 discriminatory genes whose
expression patterns, in an internal validation, identified a group
of patients who had not developed metastases at 5 years from
diagnosis despite no systemic treatment.
A method such as this for identifying patients at no risk of
developing metastases has the potential to reduce markedly the
overall amount of chemotherapy prescribed and to increase the
proportion of women who benefit from it (see Figure 1).
At present, the majority of premenopausal women with node-
negative breast cancer receive adjuvant chemotherapy, but
the absolute survival benefit from treatment (proportion cured
by the use of chemotherapy) is only around 3% at 5 years (Early
Breast Cancer Trialists’ Collaborative group, 1998b). In other
words, 33 women are treated to save one life. (The benefit is
greater at 10 years, 5.7%, but we have used the 5-year figures to
correspond with the van ‘t Veer study.) In the corresponding
control arm, survival was 83.5% at 5 years without chemotherapy.
If these women were correctly identified by molecular profiling
with 100% accuracy, and effectively removed from the treatment
arm, the survival benefit would be much greater; three lives for
16.5 treated (one life/5.5 treated) (see Figure 1). The van ‘t Veer
analysis was associated with a false-positive rate of 27% at 5 years
(‘nonmetastatic’ patients incorrectly assigned to the high-risk
‘metastatic group’). Therefore, with this level of misassignment,
the survival benefit would be three lives per 39 treated (one life/13
treated).
However, consideration should be given to the fact that there
was a false-negative rate of 9% in the poor prognosis group, that is
patients incorrectly assigned to the ‘no metastases’ group, which
would have resulted in their ‘undertreatment’. Furthermore,
clinical follow-up on this study stands at 5 years, while breast
cancer has the potential to recur beyond this time point. It will be
interesting to observe the clinical course of the surviving patients
over the next 5 years in the context of their expression profile.
Positive pathological node status is strongly associated with
poor outcome in breast cancer, but is by no means a guarantee of
systemic relapse. Other groups have used a similar method to
predict pathological lymph-node status from the expression profile
of the primary tumour (West et al, 2001; Huang et al, 2003). While
this is of interest, this is unlikely to be adopted as a clinical tool
because lymph-node status is unsatisfactory as a surrogate of the
outcome and what is required is a test of superior predictive
power.
Concerns regarding the risk of ‘under treatment’ of women with
metastatic potential, short clinical follow-up, a lack of prospective
clinical validation and limitations regarding access to this
technology means that the use of this approach is some way off
being adopted as a routine test. However trials are planned to
assess prospectively the validity of this technique in assigning
adjuvant treatment, and it is certain that it does represent a
genuine prospect for the future. Importantly, the new trials will not
only generate the statistically significant patient numbers to
validate microarray-derived prognostic signatures but also have
the potential of providing data that will allow for the refinement of
such signatures.
PREDICTING CHEMOTHERAPY RESPONSE
There is evidence to suggest that response to neoadjuvant
(presurgical) chemotherapy can be used as a surrogate of
chemotherapy survival benefit (Smith and Lipton, 2001). Several
studies have shown that complete pathological response predicts
for improved overall survival and good clinical response predicts
for improved disease-free survival (Cleator et al, 2002). It is also
reasonable to assume that good response in the neoadjuvant
setting indicates survival benefit in the adjuvant setting. There are
many descriptions of potential predictive markers of response to
neoadjuvant chemotherapy. However, as yet none of the markers
studied have proved of sufficient discriminatory power to be
employed in a clinical setting. It is anticipated that the supervised
analysis of gene expression microarray data from responsive
compared to nonresponsive tumours may allow the definition of a
panel of clinically useful discriminatory genes.
Preliminary data published in this area are promising but are
hampered, as is frequently the case, by small sample size (Sotiriou
et al, 2002; Chang et al, 2003; Pusztai et al, 2003). In the largest of
these studies, Chang et al performed expression arrays on samples
from 24 patients, 11 of which were classified as chemosensitive and
13 of which were classified as chemoresistant. Of note these two
groups were not balanced in terms of tumour size or pathological
type, both of which may influence tumour response. A total of 92
genes selected as a discriminatory gene set predicted response
correctly in six out of six independent samples (all responders).
The inherent statistical error arising from the analysis of
thousands of gene expression ratio readings on such a small
(comparatively) number of samples can be considerable, so these
results should be validated on a larger data set. It is important to
note that this set of genes may apply only to sensitivity to a
particular agent (docetaxel) or class of agent (taxanes), and it
seems possible that specific gene sets will need to be developed to
predict sensitivity to individual cytotoxic treatments. However, the
use of different microarray platforms in deriving the existing data
sets makes this difficult to assess at this time (Lee et al, 2003).
If accurate determination of chemosensitivity were achieved by
this means, the overall number receiving cytotoxic treatment
unnecessarily would decrease, and the overall survival benefit
derived, per person treated, increase accordingly, as shown in
Figure 1. However, the absolute survival benefit of patients
diagnosed with breast cancer would be unaffected and will only
improve if more effective agents are developed.
MOLECULAR PROFILING TO PREDICT PROGRESSION
OF DUCTAL CARCINOMA IN SITU
Several studies have shown that the molecular profile of the
primary tumour can predict the future development of metastases
(van ‘t Veer et al, 2002; Huang et al, 2003). This suggests that
propensity to metastasize is a feature determined early in
tumorigenesis (Bernards and Weinberg, 2002). In a similar way,
it is possible that ductal carcinoma in situ (DCIS) develops the
features that result in progression to invasive disease early in the
pathway of tumorigenesis. Indeed, microdissection of breast
cancers to isolate atypical ductal hyperplasia (ADH), in situ and
invasive components reveal very similar molecular profiles at all
stages, both in terms of expression (Ma et al, 2003) and
chromosomal aberrations (Aubele et al, 2000). Administration of
adjuvant radiotherapy following local excision of focal DCIS
results in a reduction in the incidence of development of invasive
relapse (Houghton et al, 2003). However, it is clear that even
without radiation many patients do not relapse. This may be either
because all DCIS present were excised or because any DCIS
remaining failed to progress (and these patients did not develop
new lesions). It is likely that only certain subtypes of DCIS will
progress to invasive disease and therefore derive benefit from
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expression profile that predicts a high probability of progression to
the invasive form of the disease, which could be used to target
adjuvant treatment more accurately than is achieved using clinical
and pathological scoring systems alone (Douglas-Jones et al, 1996).
However, these studies will be difficult to perform as many
patients with the so-called focal DCIS will in fact have multiple,
genetically diverse undetected lesions that follow a different
natural history.
CONCLUSIONS AND NEW HORIZONS
At present, many women with breast cancer undergo lengthy
treatments with acute and long-term toxicity, but no benefit in
survival. More accurate prediction of prognosis would significantly
reduce the amount of unnecessary chemotherapy prescribed. In
addition to the quality-of-life issues, the financial saving would be
considerable. It is estimated that an outpatient course of six cycles
of adriamycin/cyclophosphamide (AC) chemotherapy (a standard
but by no means the most expensive schedule), costs at least d2400
to deliver. Assuming that around 50% of cases diagnosed receive
adjuvant chemotherapy, this will be administered to around 20000
women with breast cancer each year in the UK. Expression
profiling is an expensive technology but if adjuvant chemotherapy
use was reduced by 70% (see Figure 1), saving at the very least 33
million pounds, it would appear much more financially viable as a
routine clinical test. If adjuvant use of taxanes increases, the saving
would escalate considerably. It is quite possible that molecular
profiling will identify a single (or handful) of markers that are
sufficient to predict prognosis with great accuracy, which would
represent a far simpler and cheaper test. Chemosensitivity testing
would result in a further reduction in the amount of chemotherapy
prescribed. Inevitably, there will be a considerable number of
women who will be identified as being resistant to conventional
cytotoxics; these patients should be considered for entry into trials
of new agents. In addition to quality-of-life improvements, this
patient group will have the opportunity of benefiting from
exposure to potentially effective novel agents.
Molecular profiling may be useful in the future in improving the
targeting of treatments in other areas of breast cancer treatment.
With the widespread introduction of mammographic screening,
the diagnosis of DCIS has increased markedly. It is difficult to
predict those cases at risk of progression to invasive disease with
the result that many women receive adjuvant radiotherapy
unnecessarily. Molecular profiling may allow the high-risk
subtypes to be identified more accurately. Similarly, accurate
identification of the subtype of metastatic breast cancer patients
who are at high risk of forming cerebral metastases would allow
exploration of the use of prophylactic cerebral irradiation as a
means of preventing their development.
Genomic or proteomic profiling will also make a contribution
to the subclassification of breast cancer. Screening the genome
for deletions and amplifications has been used successfully
to identify abnormalities associated with survival (Aubele et al,
2002) that may have a role in predicting patients at risk of relapse.
There is also considerable interest in the use of proteomic profiling
of circulating blood as a screening tool (Petricoin et al, 2002)
which, in theory, would allow cancer to be diagnosed by a blood
test.
Although the molecular profile of the tumour is a major
determinant of disease progression and response to treatment,
other factors may be of considerable importance. For example,
treatment response and toxicity may be influenced by drug
metabolism and possibly the inherent activity of DNA repair
pathways; these, in turn, are influenced by the germline genetic
profile of the patient. Assessment of such parameters (SNPs) has
the potential for predicting adverse drug reactions and for
obtaining a more accurate prediction of treatment response in
combination with the profile of the tumour.
The survival of breast cancer has improved markedly over
the last three decades, but this has been associated with
‘over treatment’ for many patients. More effective and less toxic
agents are urgently required to improve the overall survival rates
and reduce side effects but in the meantime molecular profiling
may play a role in reducing the delivery of nonbeneficial
treatment.
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